baber/WOPTO huggingface dataset:
Patent NZ-586049-A (NZ)
Title: Derivatives of 4-(2-amino-1-hydroxyethyl) phenol as agonists of the beta2 adrenergic receptor
Inventor: PUIG DURAN CARLOS
IPC: A61K31/4704
Filed: 2009-02-27
Abstract: Disclosed are N-(alkyl)-N'-{ [({ 2-hydroxy-2-[4-hydroxy-phenyl]ethyl} amino)alkyl]phenyl} urea derivatives of formula (I), wherein R4 is selected from the group consisting of an optionally substituted monocyclic or polycyclic cycloalkyl group, an optionally substituted monocyclic aryl group and a methyl group which is substituted with one or more substituents selected from aryl and aryloxy groups; and wherein the remaining substituents are as defined herein. Also disclosed is a pharmaceutical composition comprising a therapeutically effective amount of a compound as defined above, and a pharmaceutically acceptable carrier, wherein the composition optionally further comprises a therapeutically effective amount of one or more other therapeutic agents such as a corticosteroid, an antichlolinergic agent, or a PDE4 inhibitor, and wherein the composition is for the treatment of pulmonary diseases such as asthma or chronic obstructive pulmonary disease; or for pathological conditions or diseases such as pre-labor, glaucoma, neurological disorders, cardiac disorders and inflammation.
Patent NZ-591117-A (NZ)
Title: Method to separate lipids from cheese whey and fat-free whey protein product formed thereby
Inventor: DAMODARAN SRINIVASAN
IPC: A23C7/04
Filed: 2009-09-18
Abstract: 591117 Disclosed is a method of selectively separating milk fat globule membrane fragments and milk fat globules from whey comprising: (a) concentrating whey; (b) diafiltering the whey to yield a filtrate and a retentate having a conductivity of about 960 ?S/cm or less; and then (c) adjusting pH of the retentate to be less than about 6.0, wherein milk fat globule membrane fragments and milk fat globules contained in the retentate precipitate selectively from the retentate. Further disclosed is a selectively separated milk fat globule membrane fragment or globule product which is separated by the above method.
Patent NZ-592365-A (NZ)
Title: Methods and compositions for diagnosis and prognosis of renal injury and renal failure
Inventor: GRAY JEFF
IPC: G01N33/48
Filed: 2009-10-21
Abstract: Disclosed is a method for evaluating renal status in a subject, comprising: - performing one or more assays each assay comprising detecting one or more kidney injury markers present in a body fluid sample obtained previously from the subject, wherein at least one detected kidney injury marker is Thrombospondin-1; - determining on the body fluid sample one or more assay result(s); and - correlating the assay result(s) to the renal status of the subject, wherein, said correlating comprises comparing a measured concentration of Thrombospondin-1 to a threshold concentration of Thrombospondin-1 and assigning a likelihood of an event occurring or assigning a likelihood of an event not occurring when the measured concentration varies from the threshold.
Patent NZ-596889-A (NZ)
Title: Use of amide indole derivatives as modulators of ATP-binding cassette transporters
Inventor: NUMA MEHDI MICHEL JAMEL
IPC: A61K31/404
Filed: 2007-04-09
Abstract: ABSTRACT - 596889 Disclosed herein is a use of a compound of formula (Id) e.g. 1-(Benzo[d][1,3]dioxol-5-yl)-N-(2-(2-methyl-4-(1H-tetrazol-5-yl)butan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide or a pharmaceutically acceptable salt thereof for treating or lessening the severity of male infertility or pancreatic insufficiency, wherein the variables R1, R2, A, B and n shown in formula (Id) are as defined in the specification.
Patent NZ-597648-A (NZ)
Title: Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats
Inventor: STARK MARCUS
IPC: A61K31/41
Filed: 2007-10-04
Abstract: ABSTRACT - 597648 Disclosed herein is the use of an angiotensin II receptor 1 (AT-1) antagonist for the manufacture of a pharmaceutical composition comprising a therapeutically effective amount of said angiotensin II receptor 1 (AT-1) antagonist for the treatment of systemic hypertension in cats, wherein said angiotensin II receptor (AT-1) antagonist is a sartan.
Patent NZ-598558-A (NZ)
Title: Diagnostic method using diffraction of biological material
Inventor: JAMES VERONICA
IPC: A61B5/107
Filed: 2008-01-03
Abstract: NZ 598588 Disclosed is a method of detecting neoplastic disorders in a subject, the method comprising exposing a skin sample of the subject to fibre X-ray diffraction, and detecting changes in the ultrastructure of the skin sample, wherein the neoplastic disorder is prostate cancer or melanoma.
Patent NZ-599460-A (NZ)
Title: Proximity-mediated assays for detecting oncogenic fusion proteins
Inventor: SINGH SHARAT
IPC: G01N33/50
Filed: 2010-10-20
Abstract: Disclosed is a method for determining the level or activation state of an oncogenic fusion protein, the method comprising: a) contacting a cellular extract with a first binding moiety specific for a first domain of a first full-length protein under conditions suitable to transform the first full-length protein present in the cellular extract into a complex comprising the first full-length protein and the first binding moiety, wherein the first domain of the first full-length protein is absent from a corresponding oncogenic fusion protein comprising a second, different domain of the first full length protein fused to a first domain of a second, different full-length protein; b) removing the complex from step (a) from the cellular extract to form a cellular extract devoid of the first full-length protein; c) contacting the cellular extract from step (b) with a second binding moiety, a third binding moiety, and a fourth binding moiety under conditions suitable to transform the oncogenic fusion protein present in the cellular extract into a complex comprising the oncogenic fusion protein and the second, third, and fourth binding moieties, wherein the second binding moiety is specific for the second, different domain of the first full-length protein, wherein the second binding moiety is restrained on a solid support in an addressable array, wherein the third binding moiety is labelled with a facilitating moiety and is specific for one of the following: i. the first domain of the second, different full-length protein; ii. the second, different domain of the first full-length protein; or iii. the site of fusion between the second, different domain of the first full-length protein and the first domain of the second, different full-length protein, wherein the fourth binding moiety is labelled with a first member of a signal amplification pair and is specific for the first domain of the second, different full-length protein, and wherein the facilitating moiety generates an oxidising agent which channels to and reacts with the first member of the signal amplification pair; d) incubating the complex from step (c) with a second member of the signal amplification pair to generate an amplified signal; and e) detecting the amplified signal generated from the first and second members of the signal amplification pair, thereby determining the level or activation state of the oncogenic fusion protein.
Patent NZ-600181-A (NZ)
Title: Labeling article and manufacturing methods
Inventor: MALTAS JEFFREY SCOTT
IPC: B65D63/00
Filed: 2010-12-02
Abstract: Disclosed is a labelling article (10) that is secured using elastic loops formed from the label backing and release liner, where the labelling article (10) comprises a label (12), one or two elastic securing band(s) (14A,B), and a release liner (40A,B), and where the elastic securing band(s) (14A,B) is configured to be stretched to define a loop between the elastic securing band (14A,B) and the release liner (40A,B). The elastic securing band has a surface area that is less than or equal to the surface area of the first release liner.
Patent NZ-600673-A (NZ)
Title: Aminopyrimidines as syk inhibitors
Inventor: ELLIS JOHN MICHAEL
IPC: A61K31/497
Filed: 2010-12-15
Abstract: 600673 Disclosed herein is a compound of formula (I), wherein the variables are defined in the specification, and the use thereof in the treatment of a SYK-mediated disease. Specific embodiments of the compound include: (1R,4S)-4-[5-(3-cyclopropyl-5-{ [4-(trifluoromethyl)pyrimidin-2-yl]amino} phenyl)-1,3-thiazol-2-yl]-4-hydroxy-2,2-dimethylcyclohexanecarboxylic acid; (1S,4R)-4-hydroxy-2,2-dimethyl-4-[5-(3-methyl-5-{ [4-(propan-2-yloxy)pyrimidin-2-yl]amino} phenyl)-1,3-thiazol-2-yl]cyclohexanecarboxamide; and (1S,4R)-4-hydroxy-2,2-dimethyl-4-[5-(3-methyl-5-{ [4-(trifluoromethyl)pyrimidin-2-yl]amino} phenyl)-1,3-thiazol-2-yl]cyclohexanecarboxylic acid;
Patent NZ-601212-A (NZ)
Title: Nutritional composition comprising milk and phytonutrients from grass sprout
Inventor: XU XINYUE
IPC: A23C9/13
Filed: 2012-07-12
Abstract: Patent No. 601212 Disclosed is a nutritional composition made by combining milk with natural phytonutrients and optionally adding one or more nutritional or beneficial substances, the composition comprising: a protein source, a fat source, a carbohydrate source, vitamins, minerals, essential amino acids, flavonoid, optionally decosahexaenoic acid (DHA), optionally arachidonic acid (ARA), optionally fiber, and optionally a prebiotic; wherein the natural phytonutrients comprise juice, juice concentrate, or juice powder of a grass sprout, the composition is an infant formula, comprising a protein source comprising about 0.45 to about 0.7 g/ 100 KJ, a fat source comprising about 1.05 to about 1.40 g/ 100 KJ, a carbohydrate source comprising about 2.2 to about 3.3 g/ 100 KJ, vitamins, essential amino acids, minerals, and optionally decosahexaenoic acid (DHA) of about 3 to about 5 mg/100 KJ, optionally arachidonic acid (ARA) of about 5 to about 7 mg/100 KJ, optionally a supplemental calcium source, and optionally a prebiotic of about 0.1 to about 0.2 mg/ 100KJ; or the composition is a follow-up or young child formula, comprising a protein source comprising about 0.7 to about 1.2 g/ 100 KJ, a fat source comprising about 0.7 to about1.40 g/ 100 KJ, a carbohydrate source, vitamins of various amounts, essential amino acids of various amounts, minerals of various amounts, and optionally decosahexaenoic acid (DHA) of about 3 to about 5 mg/100 KJ, optionally arachidonic acid (ARA) of about 5 to about 7 mg/100 KJ, optionally a supplemental calcium source, and optionally a prebiotic of about 0.1 to about 0.2 mg/ 100KJ; wherein the nutritional composition is a powder.
Patent NZ-601704-A (NZ)
Title: Drug delivery system for dosage control having a pump and a controller
Inventor: MARTIN JAMES F
IPC: G16H20/17
Filed: 2005-06-09
Abstract: 601704 A drug delivery system that delivers a loading dose and a maintenance rate of a drug to a patient is disclosed. The system includes an infusion pump and a controller (102). The controller is programmed such that the system performs the steps of (a) calculating a loading dose based on the maintenance rate or a maintenance rate based on the loading dose; (b) administering the loading dose to the patient to achieve a desired level of effect; and (c) administering the drug at a first maintenance rate to maintain the level of effect.
Patent NZ-602603-A (NZ)
Title: Spectrometric instrument
Inventor: FOLKENBERG JACOB
IPC: G01B9/02
Filed: 2012-04-26
Abstract: Disclosed is a spectrometric instrument (2) comprising a scanning interferometer (4,6,8), a monochromatic optical radiation source (12) and an observation optical radiation source (16). The interferomenter has a beamsplitter (4) for dividing incident optical radiation into a reflected beam and a transmitted beam. The monochromatic optical radiation source (12) is arranged to launch a reference beam into the interferometer (4,6,8) along a first propagation path (14) to be initially incident on a first face (4’) of the beamsplitter (4). The observation optical radiation source (16) is arranged to launch an observation beam (18) into the interferometer (4,6,8) along a second propagation path (20) to be initially incident on the first face (4’) of beamsplitter (4) and overlap the reference beam at the first face (4’). The radiation sources (12,16) cooperate to generate a first angle (Θ) between respective first (14) and second (20) propagation paths at the first face (4’) which is larger than a divergence half-angle (α) of the observation beam (18).
Patent NZ-603968-A (NZ)
Title: Accumulation of omega-7 fatty acids in plant seeds
Inventor: WHITTLE EDWARD J
IPC: C12N15/82
Filed: 2011-06-24
Abstract: Disclosed is a nucleic acid molecule encoding a delta-9 desaturase enzyme comprising a nucleotide sequence at least 70% identical to SEQ ID NO: 1, wherein the nucleotide sequence is operably-linked to a seed-specific promoter, and wherein the SEQ ID NO: 1 is disclosed within the specification. Also disclosed is a plant seed comprising a delta-9 desaturase enzyme comprising an amino acid sequence at least 80 % identical to SEQ ID NO: 2, wherein the enzyme is encoded by a nucleotide sequence that is operably-linked to a seed-specific promoter, and wherein the SEQ ID NO: 2 is disclosed within the specification.
Patent NZ-611188-A (NZ)
Title: Method of operation of fermentation of gaseous substrate comprising hydrogen
Inventor: SENARATNE RYAN
IPC: C01B32/40
Filed: 2011-11-14
Abstract: The disclose relates to a process for increasing cell density in a microbial fermentation of a gaseous substrate, the process comprising: adding gaseous substrate that includes hydrogen (H2) and carbon monoxide (CO) into an aqueous medium in a bioreactor; said aqueous medium including an anaerobic acetogenic bacteria; measuring a rate of input of hydrogen; measuring a rate of output of hydrogen; determining an H2 uptake; and maintaining the H2 uptake such that the molar ratio of said hydrogen uptake to rate of input of hydrogen is in a range of about 0.001 to about 1.0.
Patent NZ-624780-A (NZ)
Title: Method for injecting surface water into the ground
Inventor: NIEMCZYK ANDREW
IPC: E03F1/00
Filed: 2010-04-09
Abstract: Disclosed is a method for injecting surface water into the soil beneath a ground area to improve drainage. The method includes drilling a series of vertical holes and inserting elongated pumping/drainage members into each hole extending downwardly into the soil. The pumping/drainage channel members comprise a cluster of integrally joined channel features each formed with a lengthwise extending slot opening. Surface water flows to the pumping/drainage member, enters the channels and drains down the pumping/drainage members to enhance water movement down into the soil to reduce runoff and help to recharge aquifers. Longer members are installed between shorter members in a repeating group cluster pattern to achieve more rapid injection of water deep into the subsoil. Water drains down and out of the shorter channel members percolating through the soil to an area around the upper end of the longer members to be purified by flowing through the soil in a lateral direction prior to flowing into the longer channel members. The longer channel members have upper ends installed to be a depth proximate the bottom ends of the shorter channel members, whereby soil moisture tends to enter the channels formed therein and drain downwardly through the channels to inject water into the soil around the channel member lower ends.
Patent NZ-625198-A (NZ)
Title: Undercarriage fairings for trailers
Inventor: JOHNSON JAMES MICHAEL
IPC: B62D35/02
Filed: 2012-11-21
Abstract: Disclosed is a system and method for truck or vehicle aerodynamic fairings including an undercarriage fairing. The undercarriage fairing includes multiple panels including at least two front panels and at least two rear panels. The at least two front panels are connected in a front portion under the trailer. The at least two rear panels are positioned in front of a wheel undercarriage at sides of the trailer. One of the at least two front panels and one of the at least two rear panels are interconnected on both sides of the trailer. The undercarriage fairing further includes supports connected to the frame of the trailer. The supports are connected to the at least two rear panels. and the front portion of the at least two front panels are connected directly together utilizing an angled bracket on an exterior surface. A bridge connects the front portion of the at least two front panels on an interior surface, and the bridge extends above a top edge of the at least two front panels to connect to the trailer.
Patent NZ-626033-A (NZ)
Title: Child resistant bulk dose dispensing unit
Inventor: ADLER ARI TAO
IPC: B65D50/04
Filed: 2011-03-11
Abstract: A packaging unit comprising: a container adapted to hold contents to be dispensed and having an aperture at an end thereof, the aperture being sized to dispense the contents therethrough; and a lid configured to slideably engage the container about the end thereof, the lid being slideable in a first direction between a closed position in which the lid covers the aperture and an open position in which the aperture is at least partially uncovered, wherein at least one of the container and the lid includes at least one resilient portion capable of being deflected in a direction substantially perpendicular to the first direction so as to disengage the lid from the container when in the closed position such that the lid is capable of sliding in the first direction to the open position; wherein the lid comprises a top wall and a side wall extending from the top wall, the side wall defining a lid aperture, and the container further comprising a flexible arm having the at least one resilient portion, the flexible arm further having an enlarged portion configured to be received within the lid aperture when the lid is in the closed position, the at least one resilient portion of the arm being configured such that the enlarged portion is capable of being deflected out of the lid aperture to permit movement of the lid in the first direction.
Patent NZ-631562-A (NZ)
Title: Methods for treating or preventing asthma by administering an il-4r antagonist
Inventor: ARDELEANU MARIUS
IPC: C12Q1/68
Filed: 2013-08-20
Abstract: Disclosed is the use of an anti-IL4R antibody in the manufacture of a medicament for the reduction of asthma exacerbations/improving asthma-related parameters in a subject with persistent asthma. Also disclosed is the use of an anti-IL4R antibody in the manufacture of a medicament for reducing dependence on inhaled corticosteroids and/or long-acting beta-agonists in a subject with persistent asthma.
Patent NZ-725020-A (NZ)
Title: Tire sensing system of kinetic parameters
Inventor: YI-CHUAN LIN
IPC: G08C23/00
Filed: 2016-10-07
Abstract: A tire sensing system of kinetic parameters is provided, including: at least one wave-emitting source configured to rotate with a tire, and emit at least one detection wave towards an internal surface of said tire; at least one wave sensor configured to rotate with said at least one wave-emitting source, and output a measurement signal according to a physical parameter of said at least one detection wave being reflected off said internal surface; and a processing unit configured to receive said measurement signal, record at least two instants in time during which said at least one detection wave sweeps across the footprint of said tire, and compute a kinetic parameter of said tire with said at least two instants.
Patent NZ-726067-A (NZ)
Title: System and methods for using cipher objects to protect data
Inventor: SMITH GREGORY
IPC: H04L9/32
Filed: 2015-04-17
Abstract: Systems, methods, and devices configured to build and utilize an intelligent cipher transfer object are provided. The intelligent cipher transfer object includes a set of participants protected by cloaking patterns. A portable dynamic rule set, which includes executable code for managing access to the protected set of participants, is included within the intelligent cipher transfer object. For a given user, the intelligent cipher transfer object may provide access to some of the participants while preventing access to other participants, based on the portable dynamic rule set therein.
Patent NZ-731337-A (NZ)
Title: Compounds useful as inhibitors of atr kinase
Inventor: AHMAD NADIA
IPC: A61K31/4439
Filed: 2013-12-06
Abstract: Disclosed are 2-amino-6-fluoro-N-(pyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives and analogues useful as inhibitors of ATR kinase as represented by the general formula (I); or a pharmaceutically acceptable salt thereof, wherein: R1 is–C(J1)2CN or halo; R9 is H; each J1 is independently H, methyl or ethyl; or two occurrences of J1, together with the carbon atom to which they are attached, form a 3-4 membered optionally substituted carbocyclic ring; R2 is H; halo; -CN; NH2; or a methyl or ethyl group optionally substituted with fluoro; or a C1-3aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with -O-, -NR-, -C(O)-, or –S(O)n; R3 is H; halo; alkyl optionally substituted with 1-3 occurrences of halo; cycloalkyl; heterocyclyl; -CN; or an aliphatic chain wherein up to two methylene units of the aliphatic chain are optionally replaced with -O-, -NR-, -C(O)-, or –S(O)n; R4 is Q1 or an aliphatic chain wherein up to four methylene units of the aliphatic chain are optionally replaced with -O-, -NR-, -C(O)-, or -S(O)n-; R4 is optionally substituted with 0-5 occurrences of JQ; or R3 and R4, taken together with the atoms to which they are bound, form a 5-6 membered aromatic or non-aromatic ring having 0-2 heteroatoms selected from oxygen, nitrogen and sulfur; the ring formed by R3 and R4 is optionally substituted with 0-3 occurrences of JZ; provided that the compound is not 2-amino-6-fluoro-N-[5-fluoro-4-[4-[4-(oxetan-3-yl)piperazine-1-carbonyl]-1-piperidyl]-3-pyridyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide. Also disclosed are the compounds selected from 2-amino-6-fluoro-N-(5-fluoro-4-(4-(4-(3-methyloxetan-3-yl)piperazine-1-carbonyl)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; 4-(1-(3-(2-amino-6-fluoropyrazolo[1,5-a]pyrimidine-3-carboxamido)-5-fluoropyridin-4-yl)piperidine-4-carbonyl)-1-methylpiperazine 1-oxide; 2-amino-6-fluoro-N-(5-fluoro-4-(4-(4-(1-methylazetidin-3-yl)piperazine-1-carbonyl)piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; and 2-amino-6-fluoro-N-(5-fluoro-4-(1-methyl-1H-imidazol-5-yl)pyridin-3-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide. There is also disclosed a pharmaceutical composition having properties of inhibitor of ATR protein kinase for treating cancer comprising an effective amount of a compound as defined above and a pharmaceutically acceptable carrier.
Patent NZ-737726-A (NZ)
Title: Multispecific antigen-binding molecules and uses thereof
Inventor: THURSTON GAVIN
IPC: C07K16/12
Filed: 2016-07-06
Abstract: The present disclosure provides multispecific antigen-binding molecules and uses thereof. The multispecific antigen-binding molecule is a bispecific antibody that comprises a first antigen-binding domain that specifically binds HER2, and a second antigen-binding domain that specifically binds PRLR. The simultaneous binding of the target molecule, HER2, and the internalizing effector protein, PRLR, by the bispecific antibody of the present disclosure results in the attenuation of the activity of the target molecule HER2 to a greater extent than the binding of the target molecule alone. In other embodiments the bispecific antibody of the present disclosure causes or facilitates the targeted in vitro killing of breast cancer cells. The present disclosure also provides the HER2/PRLR bispecific antibody in a pharmaceutical composition with an antibody-drug conjugate (ADC) towards HER2. This composition can be used for treating breast cancer.